Dry AMD, Intermediate
An earlier stage of dry AMD is characterized by larger drusen deposits and pigmentary changes in the macula, without the vision-threatening atrophy or neovascularization seen in advanced disease. Intermediate AMD carries an increased risk of progressing to advanced dry AMD (geographic atrophy) or wet AMD.

Symptoms
Asymptomatic or mild blurring of central vision​
​
Subtle difficulty adapting to low light
​
Slightly reduced contrast sensitivity​
Findings
Multiple medium-to-large drusen
​
Retinal pigment epithelium (RPE) changes
​
No atrophy or neovascularization​
Treatments
Lifestyle optimization: smoking cessation, AREDS2 supplements for high-risk AMD, cardiovascular risk management
​
Photobiomodulation (Valeda Light Delivery System, FDA de novo authorized for intermediate AMD)
​
Vision aids​
​
OCT monitoring: for growth or conversion to advanced AMD